Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903733 · ClinicalTrials.gov registry record · NA
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
A NA study, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 281
- Enrollment target
NCT01903733 is a NA study that has completed, run by Pfizer. The registered enrollment target is 281 participants.
The verdict
NCT01903733, a NA study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 281 participants
- Enrollment target
Study Summary
The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
Interventions
- DRUG bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2013-08-28 |
| Est. Completion | 2020-06-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01903733
The ClinicalTrials.gov registry entry for NCT01903733 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bosutinib is the first listed.
NCT01903733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01903733 about?
NCT01903733 is a clinical study titled "Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008". The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
What is the current status of trial NCT01903733?
This trial is currently completed. It is a NA study. The enrollment target is 281 participants. The study started on 2013-08-28. Estimated completion is 2020-06-05.
What interventions are being tested in trial NCT01903733?
The interventions under investigation include: bosutinib (DRUG).
Who is sponsoring clinical trial NCT01903733?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.